Versartis, Inc. (NASDAQ:VSAR) will announce its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.62) per share for the quarter.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.20). On average, analysts expect Versartis to post $-3.61 EPS for the current fiscal year and $-2.52 EPS for the next fiscal year.

Shares of Versartis, Inc. (NASDAQ:VSAR) opened at 2.45 on Wednesday. The stock’s market cap is $87.17 million. The stock’s 50 day moving average is $8.77 and its 200-day moving average is $15.41. Versartis, Inc. has a 12-month low of $2.35 and a 12-month high of $24.00.

ILLEGAL ACTIVITY NOTICE: “Versartis, Inc. (VSAR) Set to Announce Quarterly Earnings on Wednesday” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/25/versartis-inc-vsar-set-to-announce-quarterly-earnings-on-wednesday.html.

A number of brokerages have recently issued reports on VSAR. Piper Jaffray Companies downgraded shares of Versartis from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $26.00 to $4.00 in a research report on Friday, September 22nd. ValuEngine downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Barclays PLC downgraded shares of Versartis from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $28.00 to $4.00 in a research report on Friday, September 22nd. Citigroup Inc. downgraded shares of Versartis from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $23.00 to $3.00 in a research report on Monday, September 25th. Finally, BidaskClub downgraded shares of Versartis from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.22.

In other Versartis news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total transaction of $7,007,700.00. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders have sold 2,132,769 shares of company stock worth $7,014,761. 10.90% of the stock is owned by insiders.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Earnings History for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.